ORBIMED ADVISORS LLC sold 11.6% of their position (860.12K shares) of ENLIVEN THERAPEUTICS, INC. on the open market
Open‑market sale worth $39.01M — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 6/24/2026ACC: 0000947871-26-000653
Director10% Owner
Since Mar 2020
-860.12K
Net shares
Net seller
$39.01M
Total sold
4
Open market trades
0B · 4S
4
Total transactions
860.12K disposed
Non-Derivative Transactions4
Common Stock
Indirect
Shares
−24.85K
Price / share
$45.38
Trade value
$1.13M
% of position
10.1%
6/22/2026
245.73K→220.88K
Common Stock
Indirect
Shares
−1.48K
Price / share
$45.00
Trade value
$66.47K
% of position
0.7%
6/22/2026
220.88K→219.41K
Common Stock
Indirect
Shares
−787.02K
Price / share
$45.38
Trade value
$35.72M
% of position
10.7%
6/22/2026
7.39M→6.60M
Common Stock
Indirect
Shares
−46.78K
Price / share
$45.00
Trade value
$2.10M
% of position
0.7%
6/22/2026
6.60M→6.56M
Total
Net shares
−860.12K
Net value
-$39.01M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 6/22/2026 | S · Sale | −24.85K | $45.38 | $1.13M | 10.1% | 245.73K | 220.88K |
| Common Stock Indirect | 6/22/2026 | S · Sale | −1.48K | $45.00 | $66.47K | 0.7% | 220.88K | 219.41K |
| Common Stock Indirect | 6/22/2026 | S · Sale | −787.02K | $45.38 | $35.72M | 10.7% | 7.39M | 6.60M |
| Common Stock Indirect | 6/22/2026 | S · Sale | −46.78K | $45.00 | $2.10M | 0.7% | 6.60M | 6.56M |
| Total | −860.12K | -$39.01M | ||||||
Derivative Transactions0
No derivative transactions reported